Skip to main content

12 Result(s)

within Steven Akman Remove this filter

and

  1. Article

    Open Access

    Bioinformatics tools for cancer metabolomics

    It is well known that significant metabolic change take place as cells are transformed from normal to malignant. This review focuses on the use of different bioinformatics tools in cancer metabolomics studies....

    Grigoriy Blekherman, Reinhard Laubenbacher, Diego F. Cortes, Pedro Mendes… in Metabolomics (2011)

    Download PDF (253 KB) View Article

  2. No Access

    Article

    Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy

    Based on the activity of menadione (M) in the human tumor stem cell assay, we conducted a phase I trial of M in patients with advanced cancer. Forty patients (19 men, 21 women) were treated with 90 courses of ...

    Dean Lim MD, Robert J. Morgan Jr., Steven Akman, Kim Margolin… in Investigational New Drugs (2005)

  3. No Access

    Article

    Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies

    Azidothymidine (AZT, zidovudine) has been shown to reverse cisplatin resistance in cell culture. This phase I study was performed to determine the maximally tolerated dose (MTD) and dose-limiting toxicities of...

    Robert J. Morgan Jr, Edward M. Newman… in Cancer Chemotherapy and Pharmacology (2003)

  4. No Access

    Article

    Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy

    Purpose: The purpose of these sequential phase I studies was to evaluate the antiemetic efficacy and pharmacokinetics of high-dose continuous infusion prochlorperazine. Methods: A total of 52 pat...

    Robert J. Morgan Jr, Timothy Synold, Brian I. Carr… in Cancer Chemotherapy and Pharmacology (2001)

  5. No Access

    Article

    Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis

    Purpose: To evaluate the pharmacokinetics and toxicity of high-dose intravenous (i.v.) methotrexate (MTX) with leucovorin in patients with meningeal carcinomatosis. Methods: Of 16 eligible patients entered on th...

    Merry L. Tetef, Kim A. Margolin, James H. Doroshow… in Cancer Chemotherapy and Pharmacology (2000)

  6. No Access

    Chapter

    Map** Reactive Oxygen-Induced DNA Damage at Nucleotide Resolution

    The frequency of reactive oxygen (ROS)-induced DNA base damage along the human p53 and PGK1 genes was determined at nucleotide resolution by cleaving DNA at ROS-modified bases with the Nth and Fpg proteins from E...

    Steven Akman, Regen Drouin, Gerald Holmquist… in Advances in DNA Damage and Repair (1999)

  7. No Access

    Article

    Mitomycin C and menadione for the treatment of lung cancer: a phase II trial

    A phase II trial of menadione [2.5 gm/m2 as a continuous intravenous (iv) infusion over 48 hours] followed by mitomycin C (10–20 mg/m2 iv bolus) administered every 4 to 6 weeks was performed in 23 patients with a...

    Merry Tetef, Kim Margolin, Chul Ahn, Steven Akman, Warren Chow… in Investigational New Drugs (1995)

  8. No Access

    Article

    Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial

    A phase II trial of menadione (2.5 g/m2 as a continuous intravenous infusion over 48 h) followed by mitomycin C (10–20 mg/m2 i.v. bolus) administered every 4–6 weeks was performed in 43 patients with advanced gas...

    Merry Tetef, Kim Margolin, Chul Ahn… in Journal of Cancer Research and Clinical On… (1995)

  9. No Access

    Chapter

    Fluorouracil and Leucovorin in Advanced Breast Cancer

    It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15–20% of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the co...

    James H. Doroshow, Kim Margolin… in Novel Approaches to Selective Treatments o… (1993)

  10. No Access

    Article

    Phase II study of 4 ′ -deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach

    4 ′-deoxydoxorubicin (DxDx) was administered to 17 patients with locally advanced or metastatic gastric adenocarcinoma. Treatment cycles were repeated every 21 days. 15 eligible patients with a Karnofsky perfo...

    George Somlo, James Doroshow, Steven Akman, Lucille Leong… in Investigational New Drugs (1991)

  11. No Access

    Article

    3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity

    3-Deazaguanine (Dezaguanine), a purine antimetabolite, was evaluated in a phase I trial in 42 patients with advanced solid tumors. Dezaguanine was given as a weekly intravenous infusion for three consecutive w...

    Kim Margolin, James Doroshow, Lucille Leong, Steven Akman… in Investigational New Drugs (1990)

  12. No Access

    Chapter

    Effective Salvage Therapy for Refractory Disseminated Breast Cancer with 5-Fluorouracil and High-Dose Continuous Infusion Folinic Acid

    Treatment options are limited for patients with disseminated carcinoma of the breast whose disease has progressed after therapy with standard chemotherapeutic programs (1). In fact, the usefulness of testing i...

    James H. Doroshow, Lucille Leong… in The Expanding Role of Folates and Fluoropy… (1988)